O-diphenylmethoxyamine hydrochloride | 3482-34-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: O-diphenylmethoxyamine hydrochloride
• 英文别名: O-Benzyl-hydryl-hydroxamin*HCl；O-(diphenylmethyl)-hydroxylamine, hydrochloride；O-benzhydrylhydroxylamine;hydron;chloride
• CAS: 3482-34-6
• 化学式: C₁₃H₁₃NO*ClH
• 分子量: 235.713
• InChiKey: XEAXGNOKDYLPHD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.09
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  35.2
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  O-diphenylmethoxyamine hydrochloride 在 potassium carbonate 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 15.0h， 生成 3-(benzhydryloxy)-5-methyl-2-thioxothiazolidin-4-one
  参考文献：
  名称：

  α-卤代羟肟酸盐与二硫化碳的碱促进形式[3 + 2]环加成合成多取代罗丹宁

  摘要：

  开发了一种简洁实用的策略，即通过 α-卤代异羟肟酸盐与常用溶剂二硫化碳的 [3 + 2]-环加成反应，以良好的收率合成功能化的罗丹宁衍生物。本方法具有广泛的底物范围以及良好的官能团耐受性。该协议的潜在合成效用通过合成一系列含有罗丹明骨架的天然产物衍生物来证明。

  DOI：

  10.1021/acs.orglett.2c00736

文献信息

• New indenoindolone compounds
  申请人：——

  公开号：US20030125369A1

  公开（公告）日：2003-07-03

  Compound of formula (I): 1 wherein R represents hydrogen, optionally substituted alkyl or alkenyl, R 1 to R 8 , which may be identical or different, each represents hydrogen, optionally substituted alkyl, hydroxy, acyloxy, optionally substituted amino, carboxy, optionally substituted alkoxy, or alkenyloxy, or one of R 1 to R 8 forms, with another of R 1 to R 8 that is adjacent, an alkylenedioxy group, X represents oxygen or NR 16 wherein R 16 represents hydrogen, alkyl, aryl or arylalkyl, R 9 represents hydrogen, aryl, heteroaryl, or optionally substituted, saturated or unsaturated alkyl, isomers thereof, and addition salts thereof with a pharmaceutically acceptable acid or base. Medicinal products containing the same which are useful as anti-cancer agents.

  化合物的分子式（I）如下： 其中R代表氢，可选择地取代的烷基或烯基，R1至R8，可以相同也可以不同，每个代表氢，可选择地取代的烷基，羟基，酰氧基，可选择地取代的氨基，羧基，可选择地取代的烷氧基，或烯基氧基，或者R1至R8中的一个与相邻的另一个R1至R8形成烷二氧基基团，X代表氧或NR16，其中R16代表氢，烷基，芳基或芳基烷基，R9代表氢，芳基，杂芳基，或可选择地取代的饱和或不饱和烷基，其异构体，以及其与药用酸或碱的可接受盐。含有该化合物的药物制剂可用作抗癌剂。
• Cephalosporins having a carbamoylalkoxyiminoarylacetamido group at
  申请人：Glaxo Laboratories, Ltd.

  公开号：US04385177A1

  公开（公告）日：1983-05-24

  Antibiotic compounds of the general formula ##STR1## [wherein R is a phenyl, thienyl or furyl group; R.sup.a and R.sup.b, which may be the same or different, are each selected from hydrogen, C.sub.1-4 alkyl, C.sub.2-4 alkenyl C.sub.3-7 cycloalkyl, phenyl, naphthyl, thienyl, furyl, carboxy, C.sub.2-5 alkoxycarbonyl and cyano, or R.sup.a and R.sup.b together with the carbon atom to which they are attached from a C.sub.3-7 cycloalkylidene or cycloalkenylidene group; R.sup.c is hydrogen or lower alkyl; R.sup.d is hydroxy, lower alkoxy, aralkoxy or aryloxy; m and n are each 0 or 1 such that the sum of m and n is 0 or 1; and P is selected from a hydrogen atom, a halogen atom and various organic groups] and non-toxic derivatives thereof.

  一般式为##STR1##的抗生素化合物[其中R为苯基，噻吩基或呋喃基; R.sup.a和R.sup.b，可以相同也可以不同，每个都选自氢，C.sub.1-4烷基，C.sub.2-4烯基，C.sub.3-7环烷基，苯基，萘基，噻吩基，呋喃基，羧基，C.sub.2-5烷氧基羰基和氰基，或者R.sup.a和R.sup.b与它们附着的碳原子一起形成一个C.sub.3-7环烷亚基或环烯亚基; R.sup.c为氢或较低的烷基; R.sup.d为羟基，较低的烷氧基，芳基烷氧基或芳基氧基; m和n分别为0或1，使得m和n的和为0或1; P选自氢原子，卤素原子和各种有机基团]及其非毒性衍生物。
• Substituted bicyclo (2,2,1)heptanes and bicyclo (2,2,1) hept-2-enes and their pharmaceutical compositions
  申请人：NATIONAL RESEARCH DEVELOPMENT CORPORATION

  公开号：EP0013607A1

  公开（公告）日：1980-07-23

  Novel bicyclo [2,2,1] heptanes and hept-2Z-enes are substituted at the 5-position by a 6-carboxyhex-2-enyl group or a modification thereof, and at the 6-position by an aldoxime or ketoxime group which is O-substituted by an aliphatic hydrocarbon residue, an aromatic residue, or an aliphatic hydrocarbon residue substituted directly orthrough an oxygen or sulphur atom by an aromatic residue. Such compounds may be prepared by the action of an oximating agent on an intermediate which is substituted at the 6-position by an aldehydic or ketonic carbonyl group. The compounds are of value for use in pharmaceutical compositions particularly in the context of the inhibition of thromboxane activity.

  新型双环[2,2,1]庚烷和庚-2Z-烯在 5 位被 6-羧基己-2-烯基或其改性物取代，在 6 位被醛肟基或酮肟基取代，该醛肟基或酮肟基被脂肪烃残基、芳香族残基或直接通过氧原子或硫原子被芳香族残基取代的脂肪烃残基 O 取代。此类化合物可通过氧化剂对中间体的作用制备，中间体的 6 位被醛基或酮基羰基取代。这些化合物具有药物组合物的使用价值，特别是在抑制血栓素活性方面。
• Prostaglandins
  申请人：NATIONAL RESEARCH DEVELOPMENT CORPORATION

  公开号：EP0043292A2

  公开（公告）日：1982-01-06

  Novel compounds have a formula (I) wherein represents a bicyclo (2,2,1) hept-2Z-ene, bicyclo (2,2,1) heptane, 7-oxabicyclo (2,2,1) hept-2Z-ene, 7-oxabicyclo (2,2,1) heptane, bicyclo (2,2,2) oct-2Z-ene or bicyclo (2,2,2) octane substituted at the 5-position by the group R1 and at the 6-position by the group C(R2)=NR, a 6,6-dimethyl-bicyclo (3,1,1) heptane substituted at the 5- position by the group R' and at the 6-position by the group C(R2)=NR or at the 5-position by the group C(R2)=NR and at the 6-position by the group R1, a cyclohex-1-ene or cyclohexane substituted at the 4-position by the group R1 and at the 5-position by the group C(R2)=NR, or a 1-hydroxycyclopentane substituted at the 2-position by the group R1 and at the 2-position by the group C(R2)=NR, R1 is a 6-carboxyhex-2-enyl group or a modification thereof as defined herein, R2 is hydrogen, an aliphatic hydrocarbon group or an aliphatic hydrocarbon group substituted directly or through an oxygen or sulphur atom by an aromatic group, and R is a group -OR3, -OR4, -A-R3 or -N=R5 in which A is -NH-, -NH.CO-, -NH.CO.CH2N(R6)-, -NH.SO2-, -NH.CO.NH or -NH.CS.NH- and wherein R3 is an aliphatic hydrocarbon group, an aromatic group or an aliphatic hydrocarbon group substituted directly or through an oxygen or sulphur atom by an aromatic group, R4 is an aliphatic hydrocarbon group which is substituted through an oxygen atom by an aliphatic hydrocarbon group which is itself substituted by an aromatic group, R5 is an aliphatic hydrocarbon group, an aromatic group or an aliphatic hydrocarbon group substituted directly or through an oxygen or sulphur atom by an aromatic group, and R6 is hydrogen, an aliphatic hydrocarbon group, an aromatic group or an aliphatic hydrocarbon group substituted directly or through an oxygen or sulphur atom by an aromatic group, with the proviso that when R is a group -OR3, -NH.COR3 or-NH.CO.NHR3 then excludes bicyclo (2,2,1) hept-2Z-enes and bicyclo (2,2,1) heptanes. The compounds are of value for use in phar. maceutical compositions particularly in the context of the inhibition of thromboxane activity.

  新型化合物具有式 (I) 其中 代表在 5 位被基团 R1 取代、在 6 位被基团 C(R2)=NR 取代的双环(2,2,1)庚-2Z-烯、双环(2,2,1)庚烷、7-氧杂双环(2,2,1)庚烷、双环(2,2,2)辛-2Z-烯或双环(2,2,2)辛烷、在 5 位被基团 R'取代、在 6 位被基团 C(R2)=NR 取代的 6,6-二甲基双环(3,1,1)庚烷，或在 5 位被基团 C(R2)=NR 取代、在 6 位被基团 R1 取代的 6,6-二甲基双环(3,1,1)庚烷、在 4 位被基团 R1 取代且在 5 位被基团 C(R2)=NR 取代的环己-1-烯或环己烷，或在 2 位被基团 R1 取代且在 2 位被基团 C(R2)=NR 取代的 1-羟基环戊烷、R1 是本文定义的 6-羧基己-2-烯基或其改性物，R2 是氢、脂肪族烃基或直接或通过氧原子或硫原子被芳香族基取代的脂肪族烃基，R 是基团-OR3、-OR4、-A-R3 或-N=R5，其中 A 是-NH-、-NH.CO-、-NH.CO.CH2N(R6)-、-NH.SO2-、-NH.CO.NH 或 -NH.CS.其中 R3 是直接或通过氧原子或硫原子被芳香基团取代的脂肪烃基团、芳香基团或脂肪烃基团，R4 是通过氧原子被本身被芳香基团取代的脂肪烃基团，R5 是脂肪烃基团、R6是氢、脂肪族烃基、芳香族基团或直接或通过氧原子或硫原子被芳香族基团取代的脂肪族烃基，但当R是-OR3、-NH.COR3或-NH.CO.NHR3，则 不包括双环(2,2,1)庚-2Z-烯和双环(2,2,1)庚烷。这些化合物在医药组合物中具有使用价值，特别是在抑制血栓素活性方面。
• Prostaglandin intermediates
  申请人：NATIONAL RESEARCH DEVELOPMENT CORPORATION

  公开号：EP0111955A1

  公开（公告）日：1984-06-27

  Novel compounds have a formula (I) wherein represents a bicyclo [2,2,1] hept-2Z-ene, bicyclo [2,2,1] heptane, 7-oxabicyclo [2,2,1] hept-2Z-ene, 7-oxabicyclo [2,2,1] heptane, bicyclo [2,2,2] oct-2Z-ene or bicyclo [2,2,2] octane substituted at the 5-position by the group R' and at the 6-position by the group C(R2)=NR, a 6,6-dimethyl-bicyclo [3,1,1] heptane substituted at the 5-position by the group R' and at the 6-position by the group C(R2)=NR or at the 5-position by the group C(R2)=NR and at the 6-position by the group R', a cyclohex-1-ene or cyclohexane substituted at the 4-position by the group R1 and at the 5-position by the group C(R2)=NR, or a 1-hydroxycyclopentane substituted at the 2-position by the group R1 and at the 2-position by the group C(R2)=NR, R1 is a 6-carboxyhex-2-enyl group or a modification thereof as defined herein, R2 is hydrogen, an aliphatic hydrocarbon group or an aliphatic hydrocarbon group substituted directly or through an oxygen or sulphur atom by an aromatic group, and R is a group -OR3, -OR4, -A-R3 or -N=R5 in which A is -NH-, -CH.CO-, -NH.CO.CH2N(R6)-, -NH.S02-, -NH.CO.NH or -NH.CS.NH-and wherein R3 is an aliphatic hydrocarbon group, an aromatic group or an aliphatic hydrocarbon group substituted directly or through an oxygen or sulphur atom by an aromatic group, R4 is an aliphatic hydrocarbon group which is substituted through an oxygen atom by an aliphatic hydrocarbon group which is itself substituted by an aromatic group, R5 is an aliphatic hydrocarbon group, an aromatic group or an aliphatic hydrocarbon group substituted directly or through an oxygen or sulphur atom by an aromatic group, and R6 is hydrogen, an aliphatic hydrocarbon group, an aromatic group or an aliphatic hydrocarbon group substituted directly or through an oxygen or sulphur atom by an aromatic group, with the proviso that when R is a group -OR3, - NH.COR3 or -NH.CO.NHR3 then excludes bicyclo [2,2,1] hept-2Z-enes and bicyclo [2,2,1] heptanes. The compounds are of value for use in pharmaceutical compositions particularly in the context of the inhibition of thromboxane activity.

  新型化合物具有式 (I) 其中 代表在 5 位被基团 R'取代、在 6 位被基团 C(R2)=NR.取代的双环[2,2,1]庚-2Z-烯、双环[2,2,1]庚烷、7-氧杂双环[2,2,1]庚烷、双环[2,2,2]辛-2Z-烯或双环[2,2,2]辛烷、在 5 位被基团 R'取代、在 6 位被基团 C(R2)=NR 取代的 6,6-二甲基双环[3,1,1]庚烷，或在 5 位被基团 C(R2)=NR 取代、在 6 位被基团 R'取代的 6,6-二甲基双环[3,1,1]庚烷、在 4 位被基团 R1 取代、在 5 位被基团 C(R2)=NR 取代的环己-1-烯或环己烷，或在 2 位被基团 R1 取代、在 2 位被基团 C(R2)=NR 取代的 1-羟基环戊烷、R1 是本文定义的 6-羧基己-2-烯基或其改性物，R2 是氢、脂肪族烃基或直接或通过氧原子或硫原子被芳香族基取代的脂肪族烃基，R 是基团-OR3、-OR4、-A-R3 或-N=R5，其中 A 是-NH-、-CH.CO-、-NH.CO.CH2N(R6)-、-NH.S02-、-NH.CO.NH 或 -NH.CS.其中 R3 是脂肪族烃基、芳香族基团或直接或通过氧原子或硫原子被芳香族基团取代的脂肪族烃基；R4 是通过氧原子被脂肪族烃基取代的脂肪族烃基，该脂肪族烃基本身被芳香族基团取代；R5 是脂肪族烃基、R6是氢、脂肪族烃基、芳香族基团或直接或通过氧原子或硫原子被芳香族基团取代的脂肪族烃基，但当R是-OR3、-NH.COR3或-NH.CO.NHR3，则 不包括双环[2,2,1]庚-2Z-烯和双环[2,2,1]庚烷。这些化合物具有药物组合物的使用价值，特别是在抑制血栓素活性方面。